Literature DB >> 1538022

Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock.

M D Hibbard1, D R Holmes, K R Bailey, G S Reeder, J F Bresnahan, B J Gersh.   

Abstract

In cardiogenic shock complicating acute myocardial infarction, percutaneous transluminal coronary angioplasty has been reported to significantly improve the modest survival benefits afforded by emergency surgical revascularization and thrombolytic therapy. The records of all patients who underwent angioplasty for acute myocardial infarction complicated by cardiogenic shock were retrospectively reviewed to determine whether coronary angioplasty improves survival. Of the 45 patients, 28 (group 1, 62%) had successful dilation of the infarct-related artery and 17 (group 2, 38%) had unsuccessful angioplasty. The groups were similar in extent of coronary artery disease, infarct location, incidence of multivessel disease and hemodynamic variables. The overall hospital survival rate was 56% (71% in group 1 and 29% in group 2). Group 1 patients had more left main coronary artery disease, and group 2 patients were older and had a higher incidence of prior myocardial infarction. Multivariate analysis showed that the survival advantage in patients with successful angioplasty was statistically significant (p = 0.014) when these factors were taken into account. At a mean follow-up interval of 2.3 years (range 1 month to 5.6 years), there were five deaths (four cardiac and one noncardiac), for a 2.3-year survival rate of 80% in patients surviving to hospital discharge. During the follow-up period, 36% of hospital survivors had repeat hospitalization for cardiac evaluation, 8% had myocardial infarction, 8% had coronary artery bypass surgery and 24% had angina.

Entities:  

Mesh:

Year:  1992        PMID: 1538022     DOI: 10.1016/s0735-1097(10)80285-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

Review 1.  Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice.

Authors:  S G Williams; D J Wright; L B Tan
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 2.  Management of acute myocardial infarction in the elderly.

Authors:  D E Forman; M W Rich
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

3.  Predictors of outcome after percutaneous treatment for cardiogenic shock.

Authors:  A G C Sutton; P Finn; J A Hall; A A Harcombe; R A Wright; M A de Belder
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

Review 4.  Cardiogenic shock: therapy and prevention.

Authors:  W L Barry; I J Sarembock
Journal:  Clin Cardiol       Date:  1998-02       Impact factor: 2.882

5.  Acute myocardial infarction with cardiogenic shock on admission: incidence, prognostic implications, and current treatment strategies. Results from "the 60-Minutes Myocardial Infarction Project". ALKK ("Arbeitsgemeinschaft leitender Krankenhauskardiologen") Study Group.

Authors:  W Beermann; J Carlsson; J Rustige; R Schiele; J Senges; U Tebbe
Journal:  Herz       Date:  1999-08       Impact factor: 1.443

Review 6.  Primary coronary angioplasty in acute myocardial infarction.

Authors:  E D Grech; D R Ramsdale
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

7.  Therapeutic strategies for cardiogenic shock, 2006.

Authors:  Troy C Ellis; Eli Lev; Naji F Yazbek; Neal S Kleiman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-02

8.  Outcome after surgery and percutaneous intervention for cardiogenic shock and left main disease.

Authors:  Michael S Lee; Chi-Hong Tseng; Colin M Barker; Venu Menon; David Steckman; Richard Shemin; Judith S Hochman
Journal:  Ann Thorac Surg       Date:  2008-07       Impact factor: 4.330

9.  Coronary Revascularization in Cardiogenic Shock.

Authors:  Nathan Spence; J Dawn Abbott
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-01

10.  Therapeutic Strategies for Cardiogenic Shock.

Authors:  Naji F. Yazbek; Neal S. Kleiman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.